Behind The Knife: The Surgery Podcast

Journal Review in Surgical Oncology: Gastrointestinal Stromal Tumors (GISTs)

03.04.2024 - By Behind The Knife: The Surgery PodcastPlay

Download our free app to listen on your phone

Download on the App StoreGet it on Google Play

Join the Behind the Knife Surgical Oncology Team as we discuss “One versus Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial,” the randomized trial guiding duration of imatinib treatment for gastrointestinal stromal tumors (GIST).

Hosts:

- Timothy Vreeland, MD, FACS (@vreelant) is an Assistant Professor of Surgery at the Uniformed Services University of the Health Sciences and Surgical Oncologist at Brooke Army Medical Center.

- Daniel Nelson, DO, FACS (@usarmydoc24) is Surgical Oncologist and current HPB fellow at MD Anderson.

- Connor Chick, MD (@connor_chick) is a Surgical Oncology fellow at Ohio State University.

- Lexy (Alexandra) Adams, MD, MPH (@lexyadams16) is a PGY-6 General Surgery resident at Brooke Army Medical Center.

- Beth (Elizabeth) Carpenter, MD (@elizcarpenter16) is a PGY-5 General Surgery resident at Brooke Army Medical Center.

Learning Objectives:

In this episode, we discuss the article “One versus Three Years of Adjuvant Imatinib for Operable Gastrointestinal Stromal Tumor: A Randomized Trial” published in JAMA in 2012. This study demonstrated that 3 years of imatinib led to improved recurrence-free and overall survival compared to 1 year.  

Links to Paper Referenced in this Episode

https://jamanetwork.com/journals/jama/fullarticle/1105116

 ***Fellowship Application - https://forms.gle/5fbYJ1JXv3ijpgCq9***

Please visit https://app.behindtheknife.org/home to access other high-yield surgical education podcasts, videos and more.

If you liked this episode, check out our recent episodes here https://app.behindtheknife.org/listen

More episodes from Behind The Knife: The Surgery Podcast